Is arachidonic acid stimulation really a test for the response to aspirin? Time to think again?

References

• Samara WM, Gurbel PA. The role of platelet receptors and adhesion molecules in coronary artery disease. Coron Artery Dis. 2003;14(1):65–79.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Tantry US. Combination antithrombotic therapies. Circulation. 2010;121(4):569–583.
   PubMed Web of Science ®Google Scholar
• Fuster V, Sweeny JM. Aspirin: a historical and contemporary therapeutic overview. Circulation. 2011;123(7):768–778.
   PubMed Web of Science ®Google Scholar
• Campbell CL, Smyth S, Montalescot G, et al. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA. 2007;297(18):2018–2024.
   PubMed Web of Science ®Google Scholar
• Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231(25):232–235.
   PubMedGoogle Scholar
• Patrono C, Baigent C, Hirsh J, et al. American College of Chest P. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):199S–233S.
   PubMed Web of Science ®Google Scholar
• Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest. 1975;56(3):624–632.
   PubMed Web of Science ®Google Scholar
• Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A. 1975;72(8):3073–3076.
   PubMed Web of Science ®Google Scholar
• Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A. 1975;72(8):2994–2998.
   PubMed Web of Science ®Google Scholar
• Nakahata N. Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther. 2008;118(1):18–35.
   PubMed Web of Science ®Google Scholar
• FitzGerald GA, Oates JA, Hawiger J, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983;71(3):676–688.
   PubMed Web of Science ®Google Scholar
• Kuliczkowski W, Witkowski A, Polonski L, et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J. 2009;30(4):426–435.
   PubMed Web of Science ®Google Scholar
• Lordkipanidze M, Pharand C, Schampaert E, et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J. 2007;28(14):1702–1708.
   PubMed Web of Science ®Google Scholar
• Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88(3):230–235.
   PubMed Web of Science ®Google Scholar
• Kasmeridis C, Apostolakis S, Lip GY. Aspirin and aspirin resistance in coronary artery disease. Curr Opin Pharmacol. 2013;13(2):242–250.
   PubMed Web of Science ®Google Scholar
• Ertugrul DT, Tutal E, Yildiz M, et al. Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010;95(6):2897–2901.
   PubMed Web of Science ®Google Scholar
• Shiotani A, Sakakibara T, Nomura M, et al. Aspirin-induced peptic ulcer and genetic polymorphisms. J Gastroenterol Hepatol. 2010;25(Suppl 1):S31–S34.
   PubMed Web of Science ®Google Scholar
• Goodman T, Ferro A, Sharma P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol. 2008;66(2):222–232.
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet. 2006;367(9510):606–617.
   PubMed Web of Science ®Google Scholar
• Tantry US, Mahla E, Gurbel PA. Aspirin resistance. Prog Cardiovasc Dis. 2009;52(2):141–152.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, DiChiara J, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation. 2007;115(25):3156–3164.
   PubMed Web of Science ®Google Scholar
• Baigent C, Collins R, Appleby P, et al. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ. 1998;316(7141):1337–1343.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107(23):2908–2913.
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005;45(2):246–251.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Bernardo E, Sabate M, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol. 2007;50(16):1541–1547.
   PubMed Web of Science ®Google Scholar
• Michelson AD, Cattaneo M, Eikelboom JW, et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemostasis. 2005;3(6):1309–1311.
   PubMed Web of Science ®Google Scholar
• Golanski J, Chlopicki S, Golanski R, et al. Resistance to aspirin in patients after coronary artery bypass grafting is transient: impact on the monitoring of aspirin antiplatelet therapy. Ther Drug Monit. 2005;27(4):484–490.
   PubMed Web of Science ®Google Scholar
• Zimmermann N, Kurt M, Winter J, et al. Detection and duration of aspirin resistance after coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2008;135(4):947–948.
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86.
   PubMed Web of Science ®Google Scholar
• Patrono C, Coller B, FitzGerald GA, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):234S–64S.
   PubMed Web of Science ®Google Scholar
• Gori AM, Marcucci R, Migliorini A, et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol. 2008;52(9):734–739.
   PubMed Web of Science ®Google Scholar
• Bliden KP, DiChiara J, Tantry US, et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol. 2007;49(6):657–666.
   PubMed Web of Science ®Google Scholar
• Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol. 2007;49(24):2312–2317.
   PubMed Web of Science ®Google Scholar
• Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation. 2009;119(2):237–242.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol. 2005;46(10):1820–1826.
   PubMed Web of Science ®Google Scholar
• Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J. 2008;29(8):992–1000.
   PubMed Web of Science ®Google Scholar
• Patti G, Nusca A, Mangiacapra F, et al. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol. 2008;52(14):1128–1133.
   PubMed Web of Science ®Google Scholar
• Goldman S, Copeland J, Moritz T, et al. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation. 1988;77(6):1324–1332.
   PubMed Web of Science ®Google Scholar
• Goldman S, Copeland J, Moritz T, et al. Saphenous-vein graft patency 1 year after coronary-artery bypass-surgery and effects of antiplatelet therapy - results of a veterans-administration cooperative study. Circulation. 1989;80(5):1190–1197.
   PubMed Web of Science ®Google Scholar
• Goldman S, Copeland J, Moritz T, et al. Long-term graft patency (3 years) after coronary-artery surgery effects of aspirin - results of a VA cooperative study. Circulation. 1994;89(3):1138–1143.
   PubMed Web of Science ®Google Scholar
• Curzen N, Sambu N. Antiplatelet therapy in percutaneous coronary intervention: is variability of response clinically relevant? Heart. 2011;97(17):1433–1440.
   PubMed Web of Science ®Google Scholar
• Poston RS, Gu J, Brown JM, et al. Endothelial injury and acquired aspirin resistance as promoters of regional thrombin formation and early vein graft failure after coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2006;131(1):122–130.
   PubMed Web of Science ®Google Scholar
• Gluckman TJ, McLean RC, Schulman SP, et al. Effects of aspirin responsiveness and platelet reactivity on early vein graft thrombosis after coronary artery bypass graft surgery. J Am Coll Cardiol. 2011;57(9):1069–1077.
   PubMed Web of Science ®Google Scholar
• Zheng-Ming Chen. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet. 1997;349(9066):1641–1649.
   PubMed Web of Science ®Google Scholar
• The International Stroke Trial(IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet. 1997;349(9065):1569–1581.
   PubMed Web of Science ®Google Scholar
• Jeon SB, Song HS, Kim BJ, et al. Biochemical aspirin resistance and recurrent lesions in patients with acute ischemic stroke. Eur Neurol. 2010;64(1):51–57.
   PubMed Web of Science ®Google Scholar
• Fong J, Cheng-Ching E, Hussain MS, et al. Predictors of biochemical aspirin and clopidogrel resistance in patients with ischemic stroke. J Stroke Cerebrovasc Dis. 2011;20(3):227–230.
   PubMed Web of Science ®Google Scholar
• Zytkiewicz M, Gielwanowska L, Wojtasinska E, et al. Resistance to acetylsalicylic acid in patients after ischemic stroke. Pol Arch Med Wewn. 2008;118(12):727–733.
   PubMedGoogle Scholar
• Seok JI, Joo IS, Yoon JH, et al. Can aspirin resistance be clinically predicted in stroke patients? Clin Neurol Neurosurg. 2008;110(2):110–116.
   PubMed Web of Science ®Google Scholar
• Bennett D, Yan B, Macgregor L, et al. A pilot study of resistance to aspirin in stroke patients. J Clin Neurosci. 2008;15(11):1204–1209.
   PubMed Web of Science ®Google Scholar
• Berrouschot J, Schwetlick B, von Twickel G, et al. Aspirin resistance in secondary stroke prevention. Acta Neurol Scand. 2006;113(1):31–35.
   PubMed Web of Science ®Google Scholar
• Burdess A, Nimmo AF, Garden OJ, et al. Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia. Ann Surg. 2010;252(1):37–42.
   PubMed Web of Science ®Google Scholar
• Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326(6):381–386.
   PubMed Web of Science ®Google Scholar
• Ankle Brachial Index C, Fowkes FG, Murray GD, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300(2):197–208.
   PubMed Web of Science ®Google Scholar
• Saunders J, Nambi V, Kimball KT, et al. Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients. J Vasc Surg. 2011;53(3):668–675.
   PubMed Web of Science ®Google Scholar
• Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation. 2007;116(17):1971–1996.
   PubMed Web of Science ®Google Scholar
• Oscarsson A, Gupta A, Fredrikson M, et al. To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. Br J Anaesth. 2010;104(3):305–312.
   PubMed Web of Science ®Google Scholar
• Burger W, Chemnitius JM, Kneissl GD, et al. Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis. J Intern Med. 2005;257(5):399–414.
   PubMed Web of Science ®Google Scholar
• Task Force for Preoperative Cardiac Risk A, Perioperative Cardiac Management in Non-cardiac S, European Society of C, Poldermans D, Bax JJ, Boersma E, et al.Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J. 2009;30(22):2769–2812.
   PubMed Web of Science ®Google Scholar
• Rajagopalan S, Ford I, Bachoo P, et al. Platelet activation, myocardial ischemic events and postoperative non-response to aspirin in patients undergoing major vascular surgery. J Thromb Haemost. 2007;5(10):2028–2035.
   PubMed Web of Science ®Google Scholar
• Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–2222.
   PubMed Web of Science ®Google Scholar
• Patrono C, Garcia Rodriguez LA, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353(22):2373–2383.
   PubMed Web of Science ®Google Scholar
• Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol. 2010;55(25):2878–2886.
   PubMed Web of Science ®Google Scholar
• Tasdemir E, Toptas T, Demir C, et al. Aspirin resistance in patients with type II diabetes mellitus. Ups J Med Sci. 2014;119(1):25–31.
   PubMed Web of Science ®Google Scholar
• Cetin M, Kiziltunc E, Cetin ZG, et al. Acetylsalicylic Acid resistance in patients with type 2 diabetes mellitus, prediabetes & non-diabetic coronary artery disease. Pak J Med Sci. 2014;30(3):539–544.
   PubMed Web of Science ®Google Scholar
• Davi G, Catalano I, Averna M, et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med. 1990;322(25):1769–1774.
   PubMed Web of Science ®Google Scholar
• Vaduganathan M, Alviar CL, Arikan ME, et al. Platelet reactivity and response to aspirin in subjects with the metabolic syndrome. Am Heart J. 2008;156(5):1002.e1–.e7.
   PubMed Web of Science ®Google Scholar
• Mijovic R, Kovacevic N, Zarkov M, et al. Reticulated platelets and antiplatelet therapy response in diabetic patients. J Thromb Thrombolysis. 2015;40(2):203–210.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Patel A, Dharmashankar K, et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv. 2011;4(2):180–187.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Chaudhary R, et al. Antiplatelet effect durability of a novel, 24-hour, extended-release prescription formulation of acetylsalicylic acid in patients with type 2 diabetes mellitus. Am J Cardiol. 2016 Dec 15;118(12):1941–1947.
   PubMed Web of Science ®Google Scholar
• Sambu N, Curzen N. Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations. Br J Clin Pharmacol. 2011;72(4):683–696.
   PubMed Web of Science ®Google Scholar
• Gremmel T, Steiner S, Seidinger D, et al. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost. 2009;101(2):333–339.
   PubMed Web of Science ®Google Scholar
• Grove EL, Hvas AM, Johnsen HL, et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost. 2010;103(6):1245–1253.
   PubMed Web of Science ®Google Scholar
• Cotton JM, Worrall AM, Hobson AR, et al. Individualised assessment of response to clopidogrel in patients presenting with acute coronary syndromes: a role for short thrombelastography? Cardiovasc Ther. 2010;28(3):139–146.
   PubMed Web of Science ®Google Scholar
• Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol. 2005;46(9):1705–1709.
   PubMed Web of Science ®Google Scholar
• Hovens MMC, Snoep JD, Eikenboom JCJ, et al. Prevalence of persistent platelet reactivity despite use of aspirin: A systematic review. Am Heart J. 2007;153(2):175–181.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105(14):1650–1655.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Hankey GJ, Thom J, et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation. 2008;118(17):1705–1712.
   PubMed Web of Science ®Google Scholar
• Paniccia R, Antonucci E, Maggini N, et al. Assessment of platelet function on whole blood by multiple electrode aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy. Am J Clin Pathol. 2009;131(6):834–842.
   PubMed Web of Science ®Google Scholar
• Eshtehardi P, Windecker S, Cook S, et al. Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation. Am Heart J. 2010;159(5):891–8e1.
   PubMed Web of Science ®Google Scholar
• Li X, Fries S, Li R, et al. Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2014;111(47):16830–16835.
   PubMed Web of Science ®Google Scholar
• Kovacs EG, Katona E, Bereczky Z, et al. New direct and indirect methods for the detection of cyclooxygenase 1 acetylation by aspirin; the lack of aspirin resistance among healthy individuals. Thromb Res. 2013;131(4):320–324.
   PubMed Web of Science ®Google Scholar
• Kovacs EG, Katona E, Bereczky Z, et al. Evaluation of laboratory methods routinely used to detect the effect of aspirin against new reference methods. Thromb Res. 2014;133(5):811–816.
   PubMed Web of Science ®Google Scholar
• Homorodi N, Kovacs EG, Lee S, et al. The lack of aspirin resistance in patients with coronary artery disease. J Transl Med. 2016 Mar 15;14:74.
   PubMed Web of Science ®Google Scholar
• Sambu N, Dent H, Englyst N, et al. Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory biomarkers 1 year after drug-eluting stent implantation: results of the prospective, single-centre CESSATION study. Heart. 2011;97(20):1661–1667.
   PubMed Web of Science ®Google Scholar
• Sambu N, Radhakrishnan A, Englyst N, et al. “Aspirin Resistance” in ischemic stroke: insights using short thrombelastography. J Stroke Cerebrovasc Dis. 2013;22(8):1412–1419.
   PubMed Web of Science ®Google Scholar
• Frelinger AL 3rd, Furman MI, Linden MD, et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation. 2006;113(25):2888–2896.
   PubMed Web of Science ®Google Scholar
• Frelinger AL 3rd, Li Y, Linden MD, et al. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation. 2009;120(25):2586–2596.
   PubMed Web of Science ®Google Scholar
• Englyst NA, Horsfield G, Kwan J, et al. Aspirin resistance is more common in lacunar strokes than embolic strokes and is related to stroke severity. J Cereb Blood Flow Metab. 2008;28(6):1196–1203.
   PubMed Web of Science ®Google Scholar
• Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305(11):1097–1105.
   PubMed Web of Science ®Google Scholar
• Temperilli F, Rina A, Massimi I, et al. Arachidonic acid-stimulated platelet tests: identification of patients less sensitive to aspirin treatment. Platelets. 2015;26(8):783–787.
   PubMed Web of Science ®Google Scholar
• Hobson AR, Qureshi Z, Banks P, et al. Effects of clopidogrel on “aspirin specific” pathways of platelet inhibition. Platelets. 2009;20(6):386–390.
   PubMed Web of Science ®Google Scholar
• Djukanovic N, Todorovic Z, Obradovic S, et al. Clopidogrel cessation triggers aspirin rebound in patients with coronary stent. J Clin Pharm Ther. 2014;39(1):69–72.
   PubMed Web of Science ®Google Scholar
• McMahon GS, Webster SE, Hayes PD, et al. Low molecular weight heparin significantly reduces embolisation after carotid endarterectomy–a randomised controlled trial. Eur J Vasc Endovasc Surg. 2009;37(6):633–639.
   PubMed Web of Science ®Google Scholar
• Ozeki Y, Ito H, Nagamura Y, et al. 12(S)-HETE plays a role as a mediator of expression of platelet CD62 (P-selectin). Platelets. 1998;9(5):297–302.
   PubMed Web of Science ®Google Scholar
• Katoh A, Ikeda H, Murohara Tb, et al. Platelet-derived 12-hydroxyeicosatetraenoic acid plays an important role in mediating canine coronary thrombosis by regulating platelet glycoprotein IIb/IIIa activation. Circulation. 1998 Dec 22-29;98(25):2891–2898.
   Google Scholar
• Nyby MD, Sasaki M, Ideguchi Y, et al. Platelet lipoxygenase inhibitors attenuate thrombin- and thromboxane mimetic-induced intracellular calcium mobilization and platelet aggregation. J Pharmacol Exp Ther. 1996;278(2):503–509.
   PubMed Web of Science ®Google Scholar
• Johnson EN, Brass LF, Funk CD. Increased platelet sensitivity to ADP in mice lacking platelet-type 12-lipoxygenase. Proc Natl Acad Sci U S A. 1998;95(6):3100–3105.
   PubMed Web of Science ®Google Scholar
• Korotkova M, Jakobsson P-J. Persisting eicosanoid pathways in rheumatic diseases. Nat Rev Rheumatol. 2014;10(4):229–241.
   PubMed Web of Science ®Google Scholar